Hutchison China MediTech Files for IPO
Hutchison China MediTech has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 237
Why Horizon and Express Scripts Woes Might Make DepoMed Dirt Cheap
In a fresh report, Janney Capital Markets has said that bad news for Horizon Pharma is creating a buying opportunity in DepoMed.
Wave Life Sciences Sneaks Into the Market With IPO
Wave Life Sciences PTE entered the market Wednesday morning in its initial public offering (IPO).
Voyager Therapeutics IPO Ticks Up After Lower Pricing
Voyager Therapeutics has debuted after pricing its initial public offering (IPO) under the expected range.
SurgiQuest Files for IPO
SurgiQuest has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Short Sellers Continue to Decrease Bets in Major Pharma
The short interest data have been released for the October 30 settlement date, and for most of the selected pharmaceutical stocks, short interest was down.
Short Sellers Run for Cover From Major Biotechs
The short interest data are out for the October 30 settlement date, and short interest fell in selected biotech stocks.
5 BioPharma Movers That Cannot Be Ignored
Last week, a few biotech companies made absolutely massive runs, while others had serious falls.
Humana Maintains Outlook With Aetna Merger in Sight
Humana reported mixed third-quarter financial results before the markets opened on Friday.
Wall Street Hammered These 3 Biotech Stocks: Are They Really Screaming Buys?
We combed through the Merrill Lynch database and found three biotech companies that at one time or another, when they were much higher than they are now, had analysts going crazy.
CDC Reports Continued Drop in Number of Uninsured Americans
In terms of health coverage, the number of uninsured Americans is dropping, according to the Centers for Disease Control and Prevention (CDC).
What to Expect From Celgene Earnings
Celgene is scheduled to report its third-quarter financial results before the markets open on Thursday.
Why RBC Is Now So Negative Against MannKind
RBC Capital Markets downgraded MannKind on Wednesday to Underperform from a Market Perform, with a price target of a mere dollar.
Why Cara Therapeutics Shares Could Potentially Double
A Janney Capital Markets research report on Cara Therapeutics noted a fair value estimate that suggests upside of 82%.
Why 2 Analysts Are Talking Up a Pfizer-Allergan Merger
The health care sector may have sold off a fair amount since this past summer, but there is some M&A action between giants in the sector that has potential to heat it back up.